登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《ChinaXiv，2月28日，Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-02-28

  • Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia

    提交时间： 2020-02-28

    作者： Zikuan Leng 1 ; Rongjia Zhu 2 ; Wei Hou 3 ; Yingmei Feng 3 ; Hongjian Liu 4 ; Ronghua Jin 3 ; Kunlin Jin 5 ; Robert Chunhua Zhao 1 ;

    作者单位： 1.School of Life Sciences, Shanghai University; 2.Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College; 3.Beijing You’an Hospital, Capital Medical University; 4.Department of Orthopaedics, the First Affiliated Hospital of Zhengzhou University; 5.University of North Texas Health Science Center;

    内容摘要

    A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China, Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improve the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China from Jan 23, 2020. to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs could cure or significantly improve the functional outcomes of seven patients with COVID-19 pneumonia in 14 days without observed adverse effect.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：http://www.chinaxiv.org/abs/202002.00080
11浏览量
原文链接
相关报告

  • 《ChinaXiv，2月27日，Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-02-29
    • Background The COVID-19 cases increased very fast in the last two months. The mortality among critically ill patients, especially the elder ones, was relatively high. Considering that most of the dead patients were caused by severe inflammation response, it is very urgent to develop effective therapeutic agents and strategies for these patients. The human umbilical cord mesenchymal stem cells (hUCMSCs) have shown very good capability to modulate immune response and repair the injured tissue with good safety. Case Presentation Here, we reported the treatment process and clinical outcome of a 65-year-old female critically ill COVID-19 patient infected with 2019-nCoV (now called SARS-CoV-2). The significant clinical outcome and well tolerance was observed by the adoptive transfer of allogenic hUCMSCs. Conclusions Our results suggested that the adoptive transfer therapy of hUCMSCs might be an ideal choice to be used or combined with other immune modulating agents to treat the critically ill COVID-19 patients. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    16浏览量
    原文链接

  • 《2月28日_ACE2-间充质干细胞移植可改善COVID-19肺炎患者的预后》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-03-01
    • 2月28日_ACE2-间充质干细胞移植可改善COVID-19肺炎患者的预后 1.时间：2020年2月28日 2.机构或团队：上海大学；中国医学科学院基础医学研究所，北京协和医学院基础医学院；首都医科大学附属北京佑安医院；郑州大学第一附属医院;北德克萨斯大学健康科学中心 3.事件概要： ChinaXiv预印平台于2月28日发表了上海大学等发表的文章“Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia”。 文章显示，一种冠状病毒(HCoV-19)在武汉引起了新型冠状病毒病(COVID-19)的暴发，预防和逆转细胞因子风暴可能是抢救重症COVID-19肺炎患者的关键。间充质干细胞（MSC）具有广泛的免疫调节功能。该研究旨在研究从2020年1月23日起，MSC移植是否能改善中国北京佑安医院7例COVID-19肺炎患者的预后。到2020年2月16日。7例入组患者在MSC注射后14天的临床结果、炎症和免疫功能水平的变化以及不良反应。骨髓间充质干细胞可在14天内治愈或显著改善7例COVID-19肺炎患者的功能预后，未见不良反应。间充质干细胞移植后2天，所有COVID-19肺炎患者的肺功能和症状均有明显改善。其中普通2例，重症1例，治疗后10天痊愈出院。治疗后3 ~ 6 d内外周血淋巴细胞增多，过活化的细胞因子分泌免疫细胞CXCR3+CD4+ T细胞、CXCR3+CD8+ T细胞、CXCR3+ NK细胞消失。CD14+CD11c+CD11bmid调控的DC细胞群明显增多。同时, MSC治疗组相比于对照组TNF-α明显减少而il - 10水平增加。此外，基因表达谱显示MSCs为ACE2-和TMPRSS2-，表明MSCs不受COVID-19感染。因此，对于COVID-19肺炎患者，尤其是危重症患者，静脉移植MSCs是安全有效的治疗方法。 *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并 不是结论性内容，请使用者谨慎使用。 4.附件： 原文链接：http://www.chinaxiv.org/abs/202002.00080
    63浏览量
    原文链接